Radar · Life Sciences in Shanghai
Best Life Sciences Companies in Shanghai, China
The 305 best Life Sciences companies in Shanghai, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: United Imaging Healthcare.
By Rohit KhannaTrends & Stories
305companies tracked
$10.8Bdisclosed funding
1unicorns
175have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × SHANGHAI
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
40%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2017median founding year
215kcombined LinkedIn audience
73%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Shanghai
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United Imaging Healthcare 🦄 Developer and manufacturer of advanced medical imaging and radiotherapy equipment | $504M | 96 mo ago | Series B | 171 | Seungmook Lee Co-Founder | — | 3,707 patents Advanced medical imaging, AI-driven image analysis, and therapeutic ultrasound technologies. | — |
| 2 | CStone Pharma Developing and licensing novel drugs for diseases including cancer and autoimmune diseases | $410M | 68 mo ago | Public | 476 | — | — | — | 1 partnership |
| 3 | Tianjing Biological Developer of immuno-oncology drugs for treating cancer and autoimmune diseases 55Funding top 21%Market top 41%Moat top 48%Talent bottom 49% All 7 signals ▾Fundingtop 21% Markettop 41% Moattop 48% Talentbottom 49% Globalbottom 46% Techbottom 45% Newsbottom 21% Funding: Raised $380M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) Market: 318 employees (top 5% of Life Sciences) · Top-10,000,000 web property rank vs industry peers · Fliar Intelligence Index 55/100 | $380M | 28 mo ago | Public | 318 | Yan Jingwu Chairman & CEO | DrupalPHPZURB Foundation+20 | — | — |
| 4 | 3DMed Provider of personalized diagnostic treatment solutions for cancer | $365M | 67 mo ago | Series D | 215 | Simon Shung Founder | — | — | — |
| 5 | HaiHe Biopharma Developer of reformulations for cancer treatment | $333M | 46 mo ago | Series B | 181 | Ruiping Dong CEO | Bootstrapcore-jsOWL Carousel+2 | 90 patents Small-molecule inhibitors for oncology targets (PARP1, AR, MAT2A, SOS1, ENPP1) and formulations. | — |
| 6 | LianBio Developer of therapeutics for cardiorenal and oncology diseases | $313M | 62 mo ago | Public | 163 | Bing Li CEO | Webflowanime.jsGSAP+10 | — | — |
| 7 | Harbour BioMed Developer of antibody therapeutics in immunology and oncology disease | $313M | 71 mo ago | Public | 167 | Jingsong Wang Founder | PHPNginxSwiper+3 | 241 patents Bispecific antibody therapeutics targeting immune checkpoints and tumor antigens | 2 launchs · 1 partnership |
| 8 | Sangon Biotech Provider of research services and reagents and kits | $300M | 37 mo ago | Series B | 951 | — | — | — | — |
| 9 | CARsgen Developer of CAR-T cell therapies for the treatment of hematological malignancies and solid tumors | $276M | 67 mo ago | Public | 525 | Huamao Wang Co-Founder & COO | — | — | — |
| 10 | Abbisko Therapeutics Developing novel small molecule drugs for immunomodulatory pathways to treat cancer | $263M | 65 mo ago | Public | 252 | — | — | 309 patents Small-molecule kinase inhibitor drugs targeting FGFR4, CSF‑1R, CDK, CD73, PARP for cancer therapy | — |
| 11 | D3 Bio Developer novel therapeutics for cancer 40Funding top 20%Growth top 35%Talent bottom 49%Moat bottom 48% All 7 signals ▾Fundingtop 20% Growthtop 35% Talentbottom 49% Moatbottom 48% Techbottom 40% Globalbottom 38% Marketbottom 28% Funding: Raised $262M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $262M | 6 mo ago | Series B | — | George Chen Founder & CEO | WebflowMicrosoft 365jQuery+7 | — | — |
| 12 | Elpiscience Developer of checkpoint inhibitors for the treatment of cancer | $260M | 61 mo ago | Series C | 150 | — | PHPApache HTTP ServerSwiper+2 | — | — |
| 13 | Antengene Developer of small molecule drugs for the treatment of cancer and autoimmune diseases | $238M | 71 mo ago | Public | 359 | Jay Mei Founder & CEO | — | — | — |
| 14 | EpimAb Biotherapeutics Bispecific antibody therapies using its proprietary FIT-Ig platform | $219M | 62 mo ago | Series C | 49 | — | Animate.cssBootstrapApache HTTP Server+2 | 123 patents Bispecific antibody therapeutics targeting immune checkpoints and tumor antigens | — |
| 15 | Genor Biopharma Developer of biosimilar monoclonal antibodies for treating multiple diseases | $216M | 72 mo ago | Public | 222 | — | — | 45 patents Bispecific/trispecific immune‑checkpoint antibodies for cancer immunotherapy | — |
| 16 | Singlera Genomics Developer of the NGS-based platform to detect cancer 72Moat top 21%Funding top 26%Market top 30%Patents top 33% All 6 signals ▾Moattop 21% Fundingtop 26% Markettop 30% Patentstop 33% Innovationtop 41% Globalbottom 40% Moat: Editorial + unicorn rating 8/10 · IP moat: 29 patents Funding: Raised $209M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $209M | 23 mo ago | Series B | 300 | — | — | 29 patents Liquid biopsy DNA methylation biomarkers for cancer detection and tumor assessment | — |
| 17 | Siwei Biotechnology Developer of nanocarrier delivery platform for mRNA vaccines | $206M | 60 mo ago | Deadpooled | — | Li Hangwen Founder | — | — | — |
| 18 | JW Therapeutics Developer of cell immunotherapy products for cancer treatment | $200M | 71 mo ago | Public | 490 | James Li Co-Founder & CEO | — | 34 patents Small‑molecule KRAS G12C and EGFR inhibitors for targeted cancer therapy | — |
| 19 | Gracell Bio Developer of CAR T cell therapies for the treatment of cancer | $195M | 34 mo ago | Acquired | 9 | Wei Cao Founder & CEO | HugoPHPBootstrap+5 | — | — |
| 20 | OriCell Therapeutics Developer of immuno-therapeutics for cancer treatment 72Funding top 16%Patents top 27%Moat top 28%Innovation top 34% All 8 signals ▾Fundingtop 16% Patentstop 27% Moattop 28% Innovationtop 34% Newstop 36% Markettop 37% Talentbottom 49% Globalbottom 43% Funding: Raised $170M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Patents: 56 patents matched (strict assignee match) · 55 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $170M | 2 mo ago | Series D | 150 | He Xiaowen Co-Founder | — | 56 patents Patents concentrated in health & consumer products | — |
| 21 | Laekna Developer of therapeutics for cancer and liver fibrosis | $168M | 49 mo ago | Public | — | Chris Lu Founder And Ceo | — | 12 patents Combination pharmaceutical formulations for cancer therapy | 1 partnership |
| 22 | GenFleet Therapeutics Developer of drugs for treating tumors and autoimmune diseases | $166M | 53 mo ago | Public | — | Jiong Lan Co-Founder & CEO | — | 210 patents Design and synthesis of small‑molecule kinase inhibitors, macrocycles, and antibody‑drug conjugates for oncology. | — |
| 23 | TYK Medicines Developer of drugs for the treatment of cancer | $154M | 29 mo ago | Public | 100 | Wu Yusheng Founder & CEO | — | 164 patents Patents concentrated in chemistry & materials | — |
| 24 | ImmuneOnco Biopharmaceuticals Developer of therapeutic solutions for treating cancer | $146M | 62 mo ago | Public | 152 | Tian Wenzhi Founder & CEO | — | 74 patents Designing recombinant fusion proteins and antibodies for immune‑checkpoint and tumor‑antigen targeting | — |
| 25 | JIXING Developer of therapeutics for cardiovascular and ophthalmic conditions | $127M | 29 mo ago | Series D | — | Sandy Mou CEO | — | 20 patents Data storage media, brush manufacturing, ECG-based data security, sensor hubs, olefin polymerization catalysts. | — |
| 26 | Ronovo Surgical Developer of robotic surgical instruments 21Funding top 18%Moat top 31%Talent bottom 49%News bottom 42% All 7 signals ▾Fundingtop 18% Moattop 31% Talentbottom 49% Newsbottom 42% Globalbottom 36% Marketbottom 28% Techbottom 24% Funding: Raised $119M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 21/100 | $119M | 9 mo ago | Series D | — | John Ma Founder & CEO & Chairman | Animate.cssMicrosoft ASP.NETLenis+4 | — | — |
| 27 | Argo Biopharma Developer of oligonucleotide therapeutics for various diseases | $104M | 31 mo ago | Series A | — | Shiwei Xia Co-Founder | — | — | — |
| 28 | SciNeuro Developer of therapeutic solutions for the treatment of CNS disorders 29Funding top 27%Moat top 31%Talent bottom 49%Tech bottom 45% All 6 signals ▾Fundingtop 27% Moattop 31% Talentbottom 49% Techbottom 45% Globalbottom 36% Marketbottom 33% Funding: Raised $100M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $100M | 6 mo ago | Series A | 22 | Min Li Founder & CEO | WordPressMySQLPHP+23 | — | — |
| 29 | Full-Life Technologies Provider of discovery, development, production, and logistics services for of nuclear medicines 48Funding top 17%Talent top 28%Patents top 33%Growth top 35% All 9 signals ▾Fundingtop 17% Talenttop 28% Patentstop 33% Growthtop 35% Innovationtop 45% Moattop 47% Globalbottom 45% Marketbottom 32% Techbottom 22% Funding: Raised $94.3M across 8 rounds · 8 rounds over 5 yrs (1.6/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 48/100 | $94M | 1 mo ago | Series D | — | HH Ting Co-Founder And Chief Strategy Officer | PHPAnimate.cssBootstrap+6 | 24 patents Targeted radiopharmaceuticals and antibody therapeutics for cell‑surface receptors | — |
| 30 | Inxmed Developer of treatments for drug resistance and metastases in solid tumors | $84M | 46 mo ago | Series B | 50 | Francis Cao Co-Founder | — | — | — |
| 31 | Drug Farm Developer of a novel treatment for metabolic diseases | $83M | 37 mo ago | Series C | 118 | Tong Li Co-Founder & CSO | — | — | — |
| 32 | GRIT Biotechnology Developer of cell therapy to treat solid tumours | $75M | 33 mo ago | Series B | — | Liu Yarong Founder & CEO | — | 56 patents Engineered immune cell therapies and multispecific biologics for cancer immunotherapy | — |
| 33 | RONA Therapeutics Developer of oligonucleotide therapeutics to treat multiple diseases 40Patents top 31%Moat top 32%Funding top 40%Innovation top 42% All 7 signals ▾Patentstop 31% Moattop 32% Fundingtop 40% Innovationtop 42% Talentbottom 49% Globalbottom 43% Marketbottom 40% Patents: 27 patents matched (strict assignee match) · 27 filings since 2022 vs 0 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 27 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $68M | 23 mo ago | Series A | — | Stella Shi Founder | — | 27 patents RNAi therapeutics and targeted siRNA/ dsRNA delivery for disease-modifying gene regulation | — |
| 34 | Phrontline Biopharma Developer of therapeutics for various diseases 64Talent top 28%Funding top 29%Global bottom 48% All 3 signals ▾Talenttop 28% Fundingtop 29% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $60.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $60M | 6 mo ago | Seed | — | Siyi Hu Co-Founder | — | — | — |
| 35 | Hope Medicine Developer of monoclonal antibodies for the treatment of multiple diseases | $56M | 28 mo ago | Series B | — | Rui Xiao Co-Founder | PHPAnimate.cssBootstrap+6 | — | — |
| 36 | Epigenic Therapeutics Developer of gene editing therapies for a wide variety of diseases 57Funding top 26%Patents top 28%Moat top 32%Innovation top 37% All 9 signals ▾Fundingtop 26% Patentstop 28% Moattop 32% Innovationtop 37% AItop 45% Talentbottom 49% Newsbottom 42% Marketbottom 40% Globalbottom 40% Funding: Raised $52.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Patents: 43 patents matched (strict assignee match) · 43 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $52M | 9 mo ago | Series B | — | Bob Zhang Co-Founder & CEO | — | 43 patents Epigenome editing tools for therapeutic gene repression (viral, metabolic, angiogenesis targets). | — |
| 37 | Genepoint Biological Technology Platform for cryostorage and long-term preservation | $48M | 41 mo ago | Series D | — | Ding Fubin CEO | — | — | — |
| 38 | VivaVision Biotech Developer of therapeutic solutions for treating multiple eye diseases | $46M | 30 mo ago | Series E | — | Shen Wang Founder & CEO | — | — | — |
| 39 | Shize Bio Developer of stem-cell therapies to treat neurodegenerative diseases 42Funding top 33%Growth top 35%Talent top 38%Moat top 48% All 7 signals ▾Fundingtop 33% Growthtop 35% Talenttop 38% Moattop 48% Marketbottom 48% Globalbottom 29% Techbottom 16% Funding: Raised $41.7M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 42/100 | $42M | 19 mo ago | Series B | 100 | Michael Lee Founder & CEO | PHPLayuiAnimate.css+5 | — | — |
| 40 | MindRank Provider of AI-based drug candidate identification solutions for drug development 64Innovation top 19%Patents top 26%AI top 30%Moat top 38% All 8 signals ▾Innovationtop 19% Patentstop 26% AItop 30% Moattop 38% Fundingtop 40% Talentbottom 49% Marketbottom 40% Globalbottom 31% Innovation: 47 patents (top 23% of patent-holders) · 47 filings since 2022 vs 0 in 2017-21 Patents: 47 patents matched (strict assignee match) · 47 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $30M | 35 mo ago | Series A | — | Zhangming Niu Founder & CEO | — | 47 patents Novel GLP‑1 receptor agonist polymorphs/salts and kinase inhibitor heterocycles for therapeutics | — |
| 41 | Benyao Technology Robotics and artificial intelligence technology to provide automation solutions 64Funding top 37%Market top 39%AI top 45%Talent bottom 49% All 5 signals ▾Fundingtop 37% Markettop 39% AItop 45% Talentbottom 49% Globalbottom 36% Funding: Raised $29.1M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Market: 100 employees (top 20% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 64/100 | $29M | 19 mo ago | Series A | 100 | Yang Tang Founder & CEO | — | — | 3 launchs · 1 partnership |
| 42 | Shanghai Zhongke New Life Biological Technology Provider of sequencing and bioinformatics services | $28M | 26 mo ago | Series C | 90 | Chen Wei CEO | — | — | — |
| 43 | Conjustar Developer of drug conjugates for the treatment of cancer | $28M | 28 mo ago | Seed | — | Shuyi Tang CEO | — | — | — |
| 44 | Hexaell Biotech Developer of therapeutic solutions for treating severe liver diseases 48Market top 39%Funding top 44%Global bottom 29% All 3 signals ▾Markettop 39% Fundingtop 44% Globalbottom 29% Market: 100 employees (top 20% of Life Sciences) Funding: Raised $27.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $27M | 16 mo ago | Series B | 100 | — | — | — | — |
| 45 | Brattea Developer of a medical device for the treatment of hypertension | $15M | 26 mo ago | Series D | 19 | Hongguang Cao Founder | — | — | — |
| 46 | Nk-Celltech Provider of immuno-oncologic drugs for cancer 40Market top 45%Funding top 46%Global bottom 38% All 3 signals ▾Markettop 45% Fundingtop 46% Globalbottom 38% Market: 60 employees (top 31% of Life Sciences) Funding: Raised $14.9M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $15M | 11 mo ago | Series A | 60 | — | — | — | — |
| 47 | YolTech Developer of gene editing and LNP delivery platforms for therapeutics 27Funding top 37%Moat top 42%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 37% Moattop 42% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $14.1M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 27/100 | $14M | 9 mo ago | Series B | — | Yuxuan Wu Founder & CEO | — | — | — |
| 48 | Zedman Pharmaceuticals Developer of drugs for the treatment of autoimmune inflammatory diseases | $14M | 19 mo ago | Series A | — | Chen Genghui CEO | — | — | — |
| 49 | Shanghai Tianyu Technology Provider of an AI-powered protein design model 42AI top 30%Funding top 36%Talent bottom 49%Market bottom 37% All 5 signals ▾AItop 30% Fundingtop 36% Talentbottom 49% Marketbottom 37% Globalbottom 29% AI: Classified as an AI company · Product described with: ai-powered Funding: Raised $13.8M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $14M | 19 mo ago | Series A | — | Liang Hong Founder | — | — | 3 launchs |
| 50 | Milestone Biotechnologies Company solutions for various applications including single-cell mutation analysis, CDMO services and… 24Funding top 44%Talent bottom 49%Market bottom 37%Global bottom 36% All 4 signals ▾Fundingtop 44% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $13.6M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $14M | 17 mo ago | Series A | — | Zhang Jinbao Founder & CEO | — | — | — |
Top 12 Life Sciences companies in Shanghai
#1
Series D · Shanghai, Shanghai · founded 2021$94.3Mraised▾
Series D · Shanghai, Shanghai · founded 2021
Provider of discovery, development, production, and logistics services for of nuclear medicines. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals. It manufactures radiopharmaceutical drug products.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 17%Talent
top 28%Patents
top 33%Growth
top 35%Innovation
top 45%Moat
top 47%Funding: Raised $94.3M across 8 rounds · 8 rounds over 5 yrs (1.6/yr) · Last round Series D (May 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Patents: 24 patents matched (strict assignee match) · 24 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 7k LinkedIn followers — 3.3% of this cohort's audience
Activity (LinkedIn): 1 awards · 1 expansions announced in 12 mo
Funding rounds
- May 2026Series D$110M
- May 2026Conventional Debt$40M
- Sep 2025Series C$50M
- Sep 2025Conventional Debt$27M
Founders & team
Investors
Prosperity7 Ventures, Sky9 Capital, Summer Capital, Chengwei Capital, Junson Capital, Guanghua Wutong Fund
Tech stack
Alibaba Cloud CdnAnimate.CssBaidu Analytics (百度统计)BootstrapJqueryNginx
#2
Series D · Pudong, Shanghai · founded 2015 · 150 employees$170Mraised▾
Series D · Pudong, Shanghai · founded 2015 · 150 employees
Developer of immuno-therapeutics for cancer treatment. It offers CAR-T- based therapies and antibodies for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, non-small cell lung cancer, and others.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 16%Patents
top 27%Moat
top 28%Innovation
top 34%News
top 36%Market
top 37%Funding: Raised $170M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) · Last round Series D (Apr 2026)
Patents: 56 patents matched (strict assignee match) · 55 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents · Soonicorn
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: TCE Senior Scientist, Senior Scientist (In vivo CAR-T)
Funding rounds
- Apr 2026Series D$110M
- Jan 2026Series C$70M
- Feb 2023Series B$45M
- Aug 2022Series B$125M
Founders & team
Investors
RTW Investments, Qatar Investment Authority, Qiming Venture Partners, C&D, Quan Capital, Sinopharm Capital
#3
Series B · Shanghai, Shanghai · founded 2018$262Mraised▾
Series B · Shanghai, Shanghai · founded 2018
Developer novel therapeutics for cancer. The company is focusing on developing innovative medicines in oncology and immunology. The company's pipeline include D3S-001 for the treatment of advanced unresectable or metastatic colorectal cancers.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 20%Growth
top 35%Talent
bottom 49%Moat
bottom 48%Tech
bottom 40%Global
bottom 38%Funding: Raised $262M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) · Last round Series B (Dec 2025)
Growth: Fresh capital in last 24 mo
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Dec 2025Series B$108M
- Apr 2024Series A$62M
- Nov 2020Series A$200M
Founders & team
Investors
Medicxi, WuXi AppTec, Matrix Partners China, Boyu Capital, Sequoia Capital China, Temasek
Tech stack
CloudflareGoogle AnalyticsHstsHttp/3JqueryMicrosoft 365
#4
Series A · Shanghai, Shanghai · founded 2020 · 22 employees$100Mraised▾
Series A · Shanghai, Shanghai · founded 2020 · 22 employees
Developer of therapeutic solutions for the treatment of central nervous system disorders.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 27%Moat
top 31%Talent
bottom 49%Tech
bottom 45%Global
bottom 36%Market
bottom 33%Funding: Raised $100M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) · Last round Series A (Dec 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 partnerships · 1 expansions (incl. Novartis Pharma AG) announced in 12 mo
Funding rounds
- Dec 2025Series A$53M
- Nov 2025Grant (prize money)$5M
- Dec 2020Series A$100M
Founders & team
Investors
Arch Venture Partners, Boyu Capital, General Atlantic, Sequoia Capital, TF Capital, LAV
#5
Series D · Shanghai, Shanghai · founded 2019$118.7Mraised▾
Series D · Shanghai, Shanghai · founded 2019
Developer of robotic surgical instruments. It offers robots and a digital platform for minimally invasive surgery.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 18%Moat
top 31%Talent
bottom 49%News
bottom 42%Global
bottom 36%Market
bottom 28%Funding: Raised $119M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series D (Sep 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 5k LinkedIn followers — 2.4% of this cohort's audience
Funding rounds
- Sep 2025Series D$67M
- 2025Series C—
- Jun 2024Series B$41.3M
- Aug 2023Series A$27.4M
Founders & team
Investors
NRL Capital, Yipu Capital, Vivo Capital, Matrix, GGV Capital, LongRiver Investments
Tech stack
Animate.CssBaidu Analytics (百度统计)HstsJqueryLenisMicrosoft Asp.Net
#6
Seed · Pudong, Shanghai · founded 2022$60Mraised▾
Seed · Pudong, Shanghai · founded 2022
Developer of therapeutics for various diseases. It offers a proprietary dual linker payload ADCs that are delivered to and concentrated in the tumor microenvironment, and bispecific dual payload ADCs that have the benefits of dual targeting that dilever two different MOA of payloads to cancel cells simultaneously.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Talent
top 28%Funding
top 29%Global
bottom 48%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $60.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Nov 2025)
Global: Investors from 1 country beyond China
Funding rounds
- Nov 2025Seed$60M
Founders & team
Investors
Lapam Capital, Guofang Innovation, Jianxin Capital, Jifeng Ventures, Sino Biopharmaceutical, Decheng Capital
#7
Series B · Shanghai, Shanghai · founded 2021$52Mraised▾
Series B · Shanghai, Shanghai · founded 2021
Developer of gene editing therapies for a wide variety of diseases. The company uses proprietary and patented technology platform Artificial intelligence (AI) algorithms and lipid nanoparticle (LNP) medicine delivery system to deliver medicine to target cells and tissues ex vivo and in vivo in ocular, neurodegeneration, metabolic, and rare disease models.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 26%Patents
top 28%Moat
top 32%Innovation
top 37%AI
top 45%Talent
bottom 49%Funding: Raised $52.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series B (Sep 2025)
Patents: 43 patents matched (strict assignee match) · 43 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 7/10 · IP moat: 43 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 608 LinkedIn followers
Funding rounds
- Sep 2025Series B$60M
- Aug 2023Series A$32M
- Aug 2022Seed$20M
Founders & team
Investors
Qiming Venture Partners, Orbimed, Morningside, FountainBridge Capital, TigerYeah Capital, TIF
#8
Series B · Pudong, Shanghai · founded 2014 · 300 employees$208.6Mraised▾
Series B · Pudong, Shanghai · founded 2014 · 300 employees
Developer of the NGS-based platform to detect cancer. The company has methylation haplotyping technology for detecting cancer biomarkers. Tumor cells release circulating tumor DNA (ctDNA) into the blood when undergoing apoptosis or necrosis and this ctDNA is detected as cancer biomarkers. The company has developed a PanSeer assay that measures distinct tumor-specific methylation patterns in adjacent methylation sites. It can detect cancer up to four years before conventional diagnosis.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Moat
top 21%Funding
top 26%Market
top 30%Patents
top 33%Innovation
top 41%Global
bottom 40%Moat: Editorial + unicorn rating 8/10 · IP moat: 29 patents · Soonicorn
Funding: Raised $209M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) · Last round Series B (Jul 2024)
Market: 300 employees (top 6% of Life Sciences)
Funding rounds
- Jul 2024Series B$13.8M
- Jun 2022Series B$44.9M
- Dec 2020Series B$150M
- 2018Series A—
Investors
Yangzhou Guojin Investment Group, Yangzhou Longchuan Holding Group, Junci Investment, Forstone Capital, ShenZhen GTJA Investment Group, Detong Capital
#9
Series B · Shanghai, Shanghai · founded 2021$14.1Mraised▾
Series B · Shanghai, Shanghai · founded 2021
Developer of gene editing and LNP delivery platforms for therapeutics. It focuses on creating novel tools for genome editing using metagenomics data. It develops in vivo gene-editing medicines for genetic, metabolic, cancer, and cardiovascular diseases. It is researching treatments for diseases such as familial hypercholesterolemia and hereditary transthyretin amyloidosis.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 37%Moat
top 42%Talent
bottom 49%Market
bottom 40%Global
bottom 29%Funding: Raised $14.1M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (Sep 2025)
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Sep 2025Series B$45M
- Nov 2023Series A$14.1M
- Feb 2022Angel—
- Series A—
Founders & team
Investors
Decheng Capital, Guangzhou Industrial Investment Group, Beijing Huafang Investment, K2VC, AstraZeneca
#10
Series A · Pudong, Shanghai · founded 2020 · 60 employees$14.9Mraised▾
Series A · Pudong, Shanghai · founded 2020 · 60 employees
Provider of NK cell therapy for treating cancer, cellular drugs to precisely target of tumors and tumor immune microenvironment (TIME)
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Market
top 45%Funding
top 46%Global
bottom 38%Market: 60 employees (top 31% of Life Sciences)
Funding: Raised $14.9M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series A (Jul 2025)
Global: Investors from 3 countries beyond China
Funding rounds
- Jul 2025Series A$13.9M
- Jul 2022Series A$14.9M
Investors
Huagai Capital, Sirius Capital, QJ Capital, Unifortune, CASVC
#11
Public · Shanghai, Shanghai · founded 2014 · 318 employees$380Mraised▾
Public · Shanghai, Shanghai · founded 2014 · 318 employees
Developer of immuno-oncology drugs for treating cancer and autoimmune diseases. The company has developed an in-house platform to generate monoclonal antibodies through hybridoma and phage display technologies. The company's product line include Olamkicept used for treating ulcerative colitis, TJ202 for Multiple myeloma / Autoimmune diseases, TJ101 for pediatric growth hormone deficiency, TJ301 for Ulcerative colitis / Auto-immune disease, Enoblituzumab for T cell activation combined with tumor-killing, etc.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 21%Market
top 41%Moat
top 48%Talent
bottom 49%Global
bottom 46%Tech
bottom 45%Funding: Raised $380M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) · Last round Post IPO (Feb 2024)
Market: 318 employees (top 5% of Life Sciences) · Top-10,000,000 web property · Serving 2 countries incl. United States, China
Moat: Editorial + unicorn rating 5/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 6k LinkedIn followers — 2.6% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Executive Assistant to Executive Chairman
Funding rounds
- Feb 2024Post IPO$69.9M
- Sep 2020Post IPO$418M
- Jun 2018Series C$220M
- Mar 2017Series B$150M
Founders & team
Investors
Hillhouse, GIC, Alyeska Investment Group, Sphera Global Healthcare, Perceptive Advisors, Orbimed
#12
Series B · Shanghai, Shanghai · founded 2015 · 100 employees$27.4Mraised▾
Series B · Shanghai, Shanghai · founded 2015 · 100 employees
Developer of therapeutic solutions for treating severe liver diseases. The company has developed a Hepacure bioartificial candidate that is an in-vitro liver support system. The product helps in the process of material exchange, metabolism and detoxification, and then returns to the human body to remove toxins, improve the internal environment, and relieve the liver damage of the patient. Bioartificial liver therapy helps in the treatment of severe liver damage caused by various factors such as viruses, drugs, alcohol, and toxins.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Market
top 39%Funding
top 44%Global
bottom 29%Market: 100 employees (top 20% of Life Sciences)
Funding: Raised $27.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Feb 2025)
Global: Single-market focus (China)
Funding rounds
- Feb 2025Series B$27.4M
Investors
Longpan Investment, Guanghua Wutong Fund, Shanghai Healthcare Capital, Breakthrough Capital, Hyfinity Investments
Funding & investor landscape
$10.8Btotal disclosed funding
123companies funded
226disclosed rounds
2rounds last 90 days
Most active investors
Notable founders
HH Ting
Co-Founder And Chief Strategy Officer · Full-Life Technologies
HongHoi Ting
Co-Founder · Full-Life Technologies
He Xiaowen
Co-Founder · OriCell Therapeutics
George Chen
Founder & CEO · D3 Bio
Min Li
Founder & CEO · SciNeuro
John Ma
Founder & CEO & Chairman · Ronovo Surgical
Siyi Hu
Co-Founder · Phrontline Biopharma
Zhaoyuan Chen
Co-Founder & CEO · Phrontline Biopharma
Bob Zhang
Co-Founder & CEO · Epigenic Therapeutics
Yuxuan Wu
Founder & CEO · YolTech
Yan Jingwu
Chairman & CEO · Tianjing Biological
Michael Lee
Founder & CEO · Shize Bio
Prism market signals · China · country-scoped Prism corpus, 217,045 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN SHANGHAI · Health & Bio
How research on Biotechnology in Shanghai is moving
A read on the academic research around Biotechnology in Shanghai — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 372 papers.
Shanghai Jiao Tong University and peers lead 372 papers on nanoplatforms, CRISPR, and RNA cancer mechanisms, with a cautiously optimistic stance (0.54) dominated by recent breakthroughs.
372 papers · stance +0.54 · 46% breakthrough · 13% concern
top institutions
- Shanghai Jiao Tong University107
- Shanghai Ocean University33
- Shanghai University of Traditional Chinese Medicine21
- Shanghai Academy of Agricultural Sciences19
- Shanghai Institute of Materia Medica16
leading researchers
Yun Wang · Di Wang · Hao Yin · Haochen Lyu · Jianlin Shi · Jihang Chen
prism intelligence · tone & topics
94% positive · 2% critical tone
HealthPharmaceuticalsMedical ResearchAgricultureBiologyClinical Trials
▲
Breakthroughs151 · 41%
▼ 54%→39% share
▼0.7× share momentum0 median citations81% since 2021mostly methods-led
Messenger RNA research newly emerged with 7 papers, while Gene topics surged 1→18, signaling intensifying nucleic-acid-focused breakthroughs in Shanghai biotech.
rising sub-themes (early→recent)
- Gene1→18
- Enzyme1→3
- In vitro1→3
- Fluorescence2→3
Newly emergingMessenger RNA 0→7 · Identification (biology) 0→7 · Mutant 0→6
Landmark Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA · 2,740 cites
◆
Advancements133 · 36%
▲ 20%→36% share
▲1.8× share momentum0 median citations84% since 2021mostly empirical
Transcriptome research newly emerged as the top advancement sub-topic at 10 papers, with Gene knockdown and upregulation each debuting at 9, reflecting rising gene-regulation investigation.
rising sub-themes (early→recent)
- Apoptosis1→6
- Gene1→6
- In vivo2→6
- Flow cytometry1→3
- Function (biology)1→3
Newly emergingTranscriptome 0→10 · Gene knockdown 0→9 · Downregulation and upregulation 0→9
Landmark Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease · 1,583 cites
▼
Concerns42 · 11%
▲ 11%→12% share
▲1.1× share momentum0 median citations90% since 2021mostly reviews
Antibiotic resistance newly emerged alongside Resistance ecology (5 papers), suggesting growing antimicrobial-resistance concerns now entering Shanghai biotechnology research.
rising sub-themes (early→recent)
- Agriculture1→3
Newly emergingResistance (ecology) 0→5 · Gene 0→5 · Antibiotic resistance 0→3
Landmark Osteoimmunomodulation for the development of advanced bone biomaterials · 691 cites
Common questions
How many Life Sciences companies are there in Shanghai, China?
Radar tracks 305 indexable Life Sciences companies headquartered in Shanghai, China that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Shanghai, China?
The Life Sciences companies in Shanghai, China on this list have raised a combined $10.8B in disclosed equity funding across 123 funded companies.
Which is the highest-funded Life Sciences company in Shanghai, China?
United Imaging Healthcare is the highest-funded Life Sciences company in Shanghai, China, with $503.6M in disclosed equity funding.
How many Life Sciences companies in Shanghai, China are funded?
123 of the 305 Life Sciences companies in Shanghai, China on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Shanghai, China?
1 Life Sciences company in Shanghai, China on this list is valued at $1B or more.
Who are the top investors in Shanghai, China Life Sciences companies?
The most active investors in Shanghai, China Life Sciences companies on this list include Qiming Venture Partners, Spinnotec, TF Capital, Huagai Capital, Lilly Asia Ventures.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.